Create an Account - Increase your productivity, customize your experience, and engage in information you care about.
Lake Forest-based Rosetta Genomics Ltd. recently announced the Company’s first-of-its-kind microRNA classifier for intermediate thyroid nodules, RosettaGX Reveal, is now available to be utilized on ThinPrep samples. Rosetta Genomics President and CEO Ken Berlin states that studies confirm that RosettaGX Reveal produces the same high level performance on ThinPrep prepared slides as it does on direct smear from a thyroid Fine Needle Aspirate (FNA). With the projected boost to demand for Reveal from new customers who currently use ThinPrep, Rosetta Genomics is confident in converting new accounts to the product, including several large volume accounts. “These large accounts benefit from reducing the number of laboratories they need to work with across a myriad of diagnostic areas by working exclusively with Rosetta Genomics for their testing needs in these areas” added Mr. Berlin. Rosetta Genomics Ltd. is a leading developer and provider of microRNA-based and other molecular diagnostics.